Cytek Biosciences, Inc. CTKB Ratios & Valuation
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 51.7%-3.2pp | 51.8%-3.6pp | 53.5%-1.5pp | 54.4%-0.5pp | 54.9%-0.5pp | |
| Free cash flow margin | -6.2%-15.1pp | -4.4%-15.3pp | -3%-17.3pp | 5.5%0.0pp | 8.9%+8.0pp | |
| Efficiency | ||||||
| Asset turnover | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | 0.4×0.0× | |
| Inventory turnover | 2.1×+0.3× | 2.1×+0.4× | 1.9×+0.3× | 1.8×+0.3× | 1.8×+0.3× | |
| Liquidity | ||||||
| Current ratio | 4.7×-0.9× | 5×-0.8× | 5.2×-1.0× | 5.2×-2.1× | 5.6×-1.4× | |
| Quick ratio | 4.1×-0.9× | 4.4×-0.8× | 4.5×-1.0× | 4.5×-1.8× | 5×-1.1× | |
| Cash ratio | 0.4×-1.0× | 0.4×-1.1× | 1.2×-1.3× | 1×-2.4× | 1.4×-1.6× | |
| Leverage | ||||||
| Debt-to-equity | 0.1×0.0× | 0.1×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Debt-to-assets | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | 0×0.0× | |
| Per Share | ||||||
| Book value per share | $2.55-13.9% | $2.68-11.7% | $2.97+2.2% | $2.97+0.5% | $2.96-1.4% | |
| Valuation | ||||||
| Market capitalization | $577.27M+54.5% | $645.72M-22.8% | $441.47M-39.4% | $409.11M-44.0% | $513.67M-41.4% | |
| Enterprise value | $562.23M+93.7% | $634.18M-15.4% | $365.43M-36.8% | $351.87M-37.7% | $430.28M-40.3% | |
| Price / sales | 2.8×+0.9× | 3.2×-1.0× | 2.2×-1.4× | 2.1×-1.6× | 2.6×-1.8× | |
| Price / book | 1.8×+0.8× | 1.9×-0.2× | 1.2×-0.7× | 1.1×-0.8× | 1.4×-0.9× | |
| EV / sales | 2.8×+1.3× | 3.1×-0.6× | 1.9×-1.0× | 1.8×-1.1× | 2.2×-1.4× | |
| Free cash flow yield | -2.2%-6.9pp | -1.4%-4.0pp | -1.3%-5.3pp | 2.7%+1.2pp | 3.4%+3.2pp |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Cytek Biosciences, Inc.'s profit margins?
- Cytek Biosciences, Inc. (CTKB) runs a 51.7% gross margin and a -21.5% operating margin, with a -36.2% net margin.
- Where do Cytek Biosciences, Inc.'s ratios come from?
- Every ratio is computed from Cytek Biosciences, Inc.'s SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
